Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company focused on developing cancer therapies, has announced the granting of inducement awards to nine new employees. The awards, issued on August 1, 2024, consist of stock options to purchase up to 104,600 shares of common stock under the Company's 2023 Inducement Plan.
The stock options have a four-year vesting schedule, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date. The remaining shares will vest monthly at a rate of 1/48th over the following 36 months, contingent on the employee's continued service with Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di terapie contro il cancro, ha annunciato l'assegnazione di premi di indennizzo a nove nuovi dipendenti. I premi, emessi il 1 agosto 2024, consistono in opzioni per l'acquisto di fino a 104.600 azioni ordinarie secondo il Piano di Indennizzo 2023 della Società.
Le opzioni su azioni hanno un piano di maturazione di quattro anni, con il 25% delle azioni che maturano dopo un anno dalla data di inizio della maturazione. Le azioni rimanenti matureranno mensilmente a un tasso di 1/48 in un periodo di 36 mesi, a condizione che il dipendente mantenga il servizio presso Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias contra el cáncer, ha anunciado la concesión de premios de inducción a nueve nuevos empleados. Los premios, emitidos el 1 de agosto de 2024, consisten en opciones de compra de hasta 104,600 acciones ordinarias bajo el Plan de Inducción 2023 de la Compañía.
Las opciones de compra de acciones tienen un programa de adquisición de cuatro años, con el 25% de las acciones adquiriéndose en el primer aniversario de la fecha de inicio de la adquisición. Las acciones restantes se adquirirán mensualmente a una tasa de 1/48 en los siguientes 36 meses, condicionadas a la continuidad del servicio del empleado con Syndax.
신닥스 제약회사 (Nasdaq: SNDX)는 암 치료제를 개발하는 임상 단계의 생물 의약품 회사로서 아홉 명의 신규 직원에게 유인 보상을 수여한다고 발표했습니다. 이 보상은 2024년 8월 1일에 발행되었으며, 회사의 2023년 유인 계획에 따라 최대 104,600주의 보통주를 구매할 수 있는 주식 옵션으로 구성되어 있습니다.
주식 옵션은 4년의 일정으로 분할 지급되며, 1년 기념일에 25%의 주식이 지급됩니다. 나머지 주식은 이후 36개월 동안 매달 1/48의 비율로 지급되며, 이는 신닥스에서의 지속적인 고용에 따라 달라집니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies contre le cancer, a annoncé l'octroi de recompenses d'incitation à neuf nouveaux employés. Les récompenses, émises le 1er août 2024, consistent en des options d'achat pour acquérir jusqu'à 104 600 actions ordinaires dans le cadre du Plan d'Induction 2023 de la Société.
Les options d'achat d'actions ont un plan d'acquisition réparti sur quatre ans, avec 25 % des actions devenant acquises au premier anniversaire du début de l'acquisition. Les actions restantes deviennent acquises mensuellement à un taux de 1/48 au cours des 36 mois suivants, sous réserve que l'employé continue de travailler pour Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Krebstherapien konzentriert, hat die Gewährung von Induktionsprämien an neun neue Mitarbeiter bekannt gegeben. Die Prämien, die am 1. August 2024 ausgegeben wurden, bestehen aus Optionen zum Kauf von bis zu 104.600 Aktien des Stammkapitals im Rahmen des Induktionsplans 2023 des Unternehmens.
Die Aktienoptionen haben einen Vestingzeitraum von vier Jahren, wobei 25 % der Aktien am Jahrestag des Vesting-Beginns fällig werden. Die verbleibenden Aktien werden in den folgenden 36 Monaten monatlich zu einem Satz von 1/48 fällig, abhängig von der fortgesetzten Beschäftigung des Mitarbeiters bei Syndax.
- Syndax is expanding its workforce with nine new employees
- The company is using stock options as a tool to attract and retain talent
- None.
About Syndax
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302214620.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
How many shares of common stock were granted in Syndax Pharmaceuticals' inducement awards on August 1, 2024?
What is the vesting schedule for the stock options granted by Syndax Pharmaceuticals (SNDX) in August 2024?
Under which plan did Syndax Pharmaceuticals (SNDX) grant the inducement awards in August 2024?
How many new employees received inducement awards from Syndax Pharmaceuticals (SNDX) on August 1, 2024?
